Company information
- Ticker
- QCLS
- Country
- United States
- Sector
- Information Technology
- Industry
- Tech Hardware
Q/C TECHNOLOGIES Business Summary
Q/C Technologies, Inc. (QCLS), formerly TNF Pharmaceuticals, operates as a high-performance computing (HPC) infrastructure provider specializing in "quantum-class" photonic computing for the blockchain and cryptocurrency sectors. The company generates revenue through the commercialization of energy-efficient infrastructure and the deployment of its proprietary qc-LPU100™ brand of Laser Processing Units (LPUs), which utilize light-based signals rather than traditional electrical currents. By leveraging an exclusive licensing agreement with LightSolver, QCLS targets compute-intensive optimization and combinatorial problems, claiming up to 100x computational speed and a 90% reduction in energy consumption compared to standard GPUs. Primary business segments include Photonic Computing Hardware and Blockchain Infrastructure Services. Direct competitors include IonQ, Inc., Rigetti Computing, and D-Wave Quantum Inc. in the advanced computing space, as well as Riot Platforms, Inc. in the blockchain infrastructure market; QCLS distinguishes itself by positioning its optical computing paradigm as a more sustainable, room-temperature alternative to cryogenic quantum systems. The leadership team is led by Executive Chairman Joshua Silverman, who has overseen the company’s strategic pivot from clinical-stage pharmaceuticals to advanced computing. The board was significantly bolstered in January 2026 with the appointment of Chelsea Voss, a computer scientist and Member of Technical Staff at OpenAI with an MIT pedigree, bringing expertise in machine learning infrastructure and hardware reliability. The company’s advisory board features high-profile figures including strategic advisors Martin Shkreli and James Altucher, who provide guidance on financial innovation and digital infrastructure scaling. Other key technical leadership includes Senior Quantum Advisor Dr. Steven Frankel and Chief Medical Officer Dr. Mitchell Glass, the latter reflecting the company’s legacy pharmaceutical assets. Notable institutional involvement is characterized by recent shelf registrations and strategic realignments aimed at capturing the burgeoning market for post-quantum security and sustainable AI-driven computation.